Treatment of Chronic Hepatitis B with the Sequential Administration of Interferon and Lamivudine

Hepato-Gastroenterology

Volumn 50, Issue 54, 2003, Pages 2040-2042

  Hasan, Fuad ^a   Al Khaldi, Jameela ^b   Asker, Haifa ^b   Varghese, Rosh ^c   Siddique, Iqbal ^a   Al Shammali, Mohammed ^a   Al Kalaoui, Maher ^b   Al Nakib, Basil ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b AL AMIRI HOSPITAL   (Kuwait)

^c MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Hepatitis B; Interferon; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0344530467     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. WHO: Global health situation and projections and estimates. Geneva: World Health Organization, 1992.
2. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312-323.
3. Hasan F, Al khalidi J, Abu-Tahoon S, Al-Shamali M, Al-Asfoor M, Al-Nakib B: Alfa-interferon therapy for chronic hepatitis B virus infection in Kuwaiti patients. Ann Saudi Med 1997; 17:279-282.
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin R: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
5. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al: A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68.
6. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000; 46:562-568.
7. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Baca D, et al: Long term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. J Hepatol 2001; 35:406-411.
8. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology 1981; 1:431-435.
9. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, et al: Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34:573-577.
10. Schalm SW: Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence. J Hepatol 2001; 35:419-420.